Home >
Medicine Info >
Alensol D Tablet
Loading interface...

Alensol D Tablet

Manufactured byMEDSOL INDIA OVERSEAS PVT LTD
ContainsAlendronate (70 mg) + Vitamin D3 (Cholecalciferol) (5600 International units )
Description
Alensol D Tablet is a combination medicine used for the treatment of osteoporosis (a condition where bone density reduces and bones becomes weak and fragile) in men and postmenopausal women who are at risk for fractures. This medicine is not recommended for use in children or adolescents.
QUICK LINKS:
Side effectsConcernsUsage

Side effects

Major & minor side effects for Alensol D Tablet

  • Headache
  • Dizziness
  • Abdominal pain
  • Constipation
  • Diarrhea
  • Indigestion
  • Difficulty with swallowing
  • Hairloss
  • Itching
  • Muscle and joint pain
  • Unusual tiredness and weakness
  • Joint swelling

Uses of Alensol D Tablet

What is it prescribed for?

  • Osteoporosis
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The effect of this medicine can be observed within 3 weeks of administration of the dose.
  • How long do the effects of this medicine last?
    The effect of this medicine lasts for an average duration of 12-30 weeks.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit-forming tendencies were reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the drug based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to alendronate, cholecalciferol (vitamin-D3) or any other inactive ingredients present in the formulation.

Hypocalcemia

This medicine is not recommended for use in patients with decreased calcium levels in the blood.

Inability to sit or stand

This medicine is not recommended for use in patients with an inability to sit or stand upright for at least 30 minutes due to the risk of adverse effects.

Esophageal abnormalities

This medicine is not recommended for use in patients with esophageal abnormalities or who have delayed esophageal emptying due to any stricture or achalasia.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the drug based on your clinical condition.
General warnings

Severe bone, joint and/or muscle pain

This medicine may cause severe bone, muscle and/or joint pain on therapy in some patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be required based on the clinical condition.

Use in children

This medicine is not recommended for use in children or adolescents since the safety and efficacy of use are not clinically established.

Hypocalcemia

This medicine is not recommended for use in patients with hypocalcemia (decreased blood calcium levels). The low blood calcium levels should be corrected with appropriate treatment in such patients before starting therapy with this medicine. Close monitoring of blood calcium levels, appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Driving and operating machines

This medicine may cause dizziness or blurred vision in some patients. It is advised that you do not perform any activities that require high mental alertness such as driving a vehicle or operating machinery if you experience any of these symptoms after taking this medicine.

Missed Dose

If a dose is missed, take the dose on the next morning and continue with the regular dosing schedule of one tablet once a week. Two doses of this medicine should not be taken on the same day. Contact the doctor immediately if you miss a once-weekly dose for further instructions.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Calcitriol

Nonsteroidal anti-inflammatory drugs

Deferasirox

Etecalcetide

Disease interactions

Osteonecrosis of the jaw (ONJ)

This medicine should be used with caution in patients undergoing invasive dental procedures due to the increased risk of osteonecrosis of the jaw (ONJ). Therapy with the medicine may need to be discontinued based on the clinical condition of the patient.

Renal Dysfunction

This medicine should be used with caution in patients with kidney diseases due to the increased risk of adverse effects. Regular monitoring of kidney function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition. This medicine is not recommended for use in patients with creatinine clearance less than 35 ml/min.

Active upper gastrointestinal disorders

This medicine should be used with extreme caution in patients with active upper gastrointestinal disorders due to the increased risk of adverse effects. Close monitoring of the clinical condition, appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition. This medicine is not recommended for use in patients with esophageal abnormalities or who have delayed esophageal emptying due to any stricture or achalasia.

Asthma

Caution is advised while using this medicine in patients with asthma due to the increased risk of worsening of the patient's condition. Close monitoring of such patients for any adverse effects is necessary during treatment with this medicine.

Electrolyte imbalance

This medicine is not recommended for use in patients with higher blood levels of phosphorous due to the increased risk of adverse effects. The blood phosphorous and calcium levels should be corrected with appropriate treatment in such patients before starting therapy with this medicine. Close monitoring of blood electrolyte concentrations, appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Arrhythmias

This medicine should be used with caution in patients with or predisposed to cardiac arrhythmias due to the increased risk of adverse effects. Regular monitoring of heart function is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Liver dysfunction

This medicine should be used with caution in patients with liver diseases due to the increased risk of adverse effects. Regular monitoring of liver function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Food interactions
The desired effects of this medicine will not be achieved if it is taken along with food. It is advised to take this medicine first thing in the morning and at least 30 minutes before eating or drinking anything.
The combined use of this medicine and products containing calcium, magnesium, aluminum, or iron may reduce the effectiveness of this medicine. It is recommended not to take such products for at least 30 minutes after taking this medicine. It is advised that you inform the doctor about all your medicines including herbs and supplements before beginning treatment with this medicine to avoid such interactions.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Take this medicine on an empty stomach or as instructed by the doctor. Do not take in larger amounts than advised/prescribed. It is recommended not to have any food, beverages, or medicines including vitamins or antacids for at least 30 minutes after taking this medicine. Consult the doctor if you experience any undesirable side effects. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

To be taken on an empty stomach

To be taken in morning

Does not cause sleepiness

How it works
Alendronate increases bone thickness and reduces the chances of bone breakage. Cholecalciferol (vitamin-D3), acts by promoting the absorption of calcium, phosphates and Vitamin A from different organs and helps in maintaining muscle strength and balance.
Legal Status

Approved

Approved

Unknown

Approved

Classification

Category

Bisphosphonates

Schedule

Schedule H

[Internet]. Merck.ca. 2019 [cited 10 January 2019]. Available from:

https://www.merck.ca/static/pdf/FOSAVANCE-CI_E.pdf

[Internet]. Sandoz.ca. 2019 [cited 10 January 2019]. Available from:

https://www.sandoz.ca/sites/www.sandoz.ca/files/Alendronate-Cholecalciferol%20TAB%20Monograph.pdf

Bentexo 70 mg/ 5,600 IU tablets - Summary of Product Characteristics (SmPC) - (eMC) [Internet]. Medicines.org.uk. 2019 [cited 17 June 2019]. Available from:

https://www.medicines.org.uk/emc/product/10126/smpc

Alendronate: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2017 [cited 18 August 2017]. Available from:

https://medlineplus.gov/druginfo/meds/a601011.html
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 17 Jun 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.